Exclusive: An industry consortium wants to standardize cell tracking for regenerative meds. Could that avert a disaster?
In the fast-moving world of regenerative medicine, the open secret among industry experts is that manufacturing is exceedingly difficult and will take a Herculean effort to scale. Left behind in that shuffle have been new advances in how drugmakers actually keep track of where a patients’ cells are going — and that could leave the field ripe for a disaster.
As part of a broad consortium of biopharma and tech companies working to drive new standards for advanced therapies, San Francisco’s Vineti plans to create what it calls a “modern patient ID” that can track human cells from apheresis centers through a complicated manufacturing supply chain and back into those patients.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,300+ biopharma pros reading Endpoints daily — and it's free.